公开(公告)号：US10709667B2

公开(公告)日：2020-07-14

申请号：US16403183

申请日：2019-05-03

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Daniel G. Anderson ,  Robert S. Langer ,  Tram T. Dang

IPC: A61K9/16 ,  A61K9/00 ,  A61K31/573 ,  A61K45/06 ,  A61K35/39 ,  G01N33/50 ,  A61L27/38 ,  A61L27/48 ,  A61L27/52 ,  A61L27/54 ,  C12N5/071

Abstract: A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

公开(公告)号：US20200016085A1

公开(公告)日：2020-01-16

申请号：US16584170

申请日：2019-09-26

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Arturo J. Vegas ,  Joshua C. Doloff ,  Omid Veiseh ,  Minglin Ma ,  Robert S. Langer ,  Daniel G. Anderson

IPC: A61K9/50 ,  C08B37/00 ,  A61K35/39 ,  C12N5/00 ,  C12N5/071 ,  A61K9/00 ,  A61L29/08 ,  A61L31/10 ,  A61L33/08

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

公开(公告)号：US20190262272A1

公开(公告)日：2019-08-29

申请号：US16408899

申请日：2019-05-10

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Arturo J. Vegas ,  Minglin Ma ,  Kaitlin M. Bratlie ,  Daniel G. Anderson ,  Robert S. Langer

IPC: A61K9/50 ,  A61K35/39 ,  A61K45/06 ,  C08B37/00 ,  A61K9/00

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.

公开(公告)号：US20190233816A1

公开(公告)日：2019-08-01

申请号：US16256003

申请日：2019-01-24

Applicant: Massachusetts Institute of Technology

Inventor： Robert Samuel LANGER ,  Hao Yin ,  Daniel G. Anderson ,  Wen Xue ,  Chun-Qing Song

IPC: C12N15/113 ,  A61K31/7105 ,  C12N15/85 ,  C12N15/90 ,  C12N9/22

CPC classification number: C12N15/113 ,  A61K31/7105 ,  C12N9/22 ,  C12N15/111 ,  C12N15/85 ,  C12N15/907 ,  C12N2310/20 ,  C12N2310/343 ,  C12N2320/53 ,  C12Y301/11002 ,  C12N2310/322 ,  C12N2310/3531

Abstract: The disclosure relates to compositions comprising and methods for chemical modification of single guide RNA (sgRNA), tracrRNA and/or crRNA used individually or in combination with one another or Cas system components. Compositions comprising modified ribonucleic acids have been designed with chemical modification for even higher efficiency as unmodified native strand of sgRNA. Administration of modified ribonucleic acids will allow decreased immune response when administered to a subject, increased stability, increased editing efficiency and facilitated in vivo delivery of sgRNA via various delivery platforms. The disclosure also relates to methods of decreasing off-target effect of CRISPR and a CRISPR complex.

公开(公告)号：US10285949B2

公开(公告)日：2019-05-14

申请号：US15208192

申请日：2016-07-12

Applicant: Massachusetts Institute of Technology ,  THE CHILDREN'S MEDICAL CENTER CORPORATION

Inventor： Arturo J. Vegas ,  Minglin Ma ,  Kaitlin M. Bratlie ,  Daniel G. Anderson ,  Robert S. Langer

IPC: A61K9/00 ,  A61K9/50 ,  A61K9/51 ,  A61K35/39 ,  A61K45/06 ,  C08B37/00

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.

公开(公告)号：US20190083495A1

公开(公告)日：2019-03-21

申请号：US16081654

申请日：2017-04-04

Applicant: Massachusetts Institute of Technology

Inventor： Joshua C. Doloff ,  Shady Farah ,  Omid Veiseh ,  Arturo J. Vegas ,  Robert S. Langer ,  Daniel G. Anderson

IPC: A61K31/519 ,  A61K31/4709 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/416 ,  A61K31/444 ,  A61K31/496 ,  A61K31/404 ,  A61K31/553 ,  A61K31/551 ,  A61K31/5025

Abstract: Described herein are methods of preventing or reducing fibrosis comprising administering CSF1R inhibitors, coating formulations comprising CSF1R inhibitors, coatings comprising CSF1R inhibitors for implantable medical devices, CSF1R inhibitor coated implantable medical devices, as well as corresponding embodiments comprising additional agents.

公开(公告)号：US20170355799A1

公开(公告)日：2017-12-14

申请号：US15621391

申请日：2017-06-13

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Omid Veiseh ,  Volkan Yesilyurt ,  Arturo Vegas ,  Joshua Doloff ,  Daniel G. Anderson ,  Robert S. Langer

IPC: C08F230/02 ,  A61L29/08 ,  A61L27/16 ,  A61L27/54 ,  A61K35/12 ,  A61K9/50 ,  A61L27/38 ,  C08F220/38 ,  A61L29/16 ,  A61L29/04 ,  A61L31/04 ,  A61L31/10 ,  A61L27/56 ,  A61L31/16 ,  A61L27/34 ,  A61L27/52

Abstract: Zwitterionic polymers or biocompatible polymers with improved properties for cell encapsulation, coating of devices, or a combination thereof are described. The biocompatible polymer contains a zwitterionic monomer, a monomer with a reactive side chain, and optionally another hydrophobic monomer or a neutral hydrophilic monomer. The zwitterionic polymers are cross-linked with a cross-linker via covalent bond to form a zwitterionic hydrogel in the presence of cells. Also provided, are methods of making and using the zwitterionic polymers.

公开(公告)号：US20170239397A1

公开(公告)日：2017-08-24

申请号：US15588475

申请日：2017-05-05

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Arturo J. Vegas ,  Joshua C. Doloff ,  Omid Veiseh ,  Minglin Ma ,  Robert S. Langer ,  Daniel G. Anderson

IPC: A61L29/08 ,  A61L33/08 ,  A61K9/00 ,  C07D487/04 ,  A61K35/39 ,  C12N5/00 ,  A61K9/50 ,  C12N5/071 ,  A61L31/10 ,  C08B37/00

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

公开(公告)号：US20170226232A1

公开(公告)日：2017-08-10

申请号：US15341110

申请日：2016-11-02

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Arturo J. Vegas ,  Joshua C. Doloff ,  Omid Veiseh ,  Minglin Ma ,  Robert S. Langer ,  Daniel G. Anderson

IPC: C08B37/00 ,  A61K35/39 ,  A61L29/08 ,  A61K9/48

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

公开(公告)号：US20170095514A1

公开(公告)日：2017-04-06

申请号：US15379718

申请日：2016-12-15

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Minglin Ma ,  Daniel G. Anderson ,  Robert S. Langer ,  Omid Veiseh ,  Arturo Jose Vegas ,  Joshua Charles Doloff ,  Delai Chen ,  Christian J. Kastrup

IPC: A61K35/39 ,  A61K9/00 ,  B01J13/04 ,  A61K9/50

CPC classification number: A61K9/0024 ,  A61K9/4833 ,  A61K9/4866 ,  A61K9/5036 ,  A61K9/5078 ,  A61K9/5089 ,  A61K35/39 ,  A61K45/06 ,  A61K2035/126 ,  A61K2035/128 ,  B01J13/046

Abstract: Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.